SFSahar J. Farahani

Sahar J. Farahani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sahar J. Farahani has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Joshua Jing Xi Li

    Department of Pathology, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China

    3 shared publications
  • Philippe Vielh

    Department of Pathology Medipath and American Hospital of Paris Paris France

    2 shared publications
  • Taulant Muka

    Epistudia Bern Switzerland

    2 shared publications
  • Alex H. Lin

    Department of Pathology, School of Clinical Medicine The University of Hong Kong Pokfulam Hong Kong

    1 shared publication
  • Beatrice Minder

    Public Health & Primary Care Library University Library of Bern, University of Bern Bern Switzerland

    1 shared publication
  • Hamidreza Raeisi‐Dehkordi

    Department of Global Public Health and Bioethics, Julius Center for Health Sciences and Primary Care University Medical Center (UMC) Utrecht, Utrecht University Utrecht the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Performance of the Monoclonal Antibody B72.3 in Diagnosis of Malignant Carcinomatous Serous Effusions—A Systematic Review and Meta‐Analysis of Diagnostic Performance

    by Alex H. Lin, Matthew Hsu, Joanna K. M. Ng, Sahar J. Farahani, Joshua J. X. Li, Jana Nano, Hamidreza Raeisi‐Dehkordi, Wilson Tang, Philippe Vielh, Taulant Muka

    Objectives: Immunocytochemistry is often required in the cytologic assessment of malignant serous effusion, particularly for differentiating metastatic carcinoma from mesothelioma. To summarise the diagnostic performance of the monoclonal antibody B72.3, a systematic review and meta‐analysis was conducted.Methods: Five databases were searched for relevant studies and reviewed for data extraction and risk of bias assessment. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under curve of summary receiver operating characteristics (AUC‐SROC) were calculated for the diagnostic performance of B72.3. Heterogeneity and publication bias were assessed by the I2 index and Deeks' funnel plot.Results: In total, 19 studies (1159 cases) were included. Overall pooled sensitivity and specificity were 0.76 (0.72–0.79) and 0.90 (0.74–1.00), respectively. The NLR, PLR and DOR were 0.27 (0.21–0.34), 7.66 (< 0.001–20.46) and 28.26 (0–75.96), respectively. The AUC‐SROC was 0.98, indicating a good overall diagnostic accuracy for B72.3. Subgroup analysis for adenocarcinoma (0.75, 0.71–0.79), mesothelioma (0.92, 0.85–0.98) and benign/reactive mesothelial cells (0.96, 0.93–1.00) showed similar sensitivity and specificity, while the sensitivity for adenocarcinomas of the gastrointestinal/hepatobiliary tract (0.56, 0.41–0.71) and breast (0.55, 0.38–0.71) was significantly lower. High heterogeneity was observed in the majority of our analyses, while no evidence of publication bias was identified.Conclusions: B72.3 has an acceptable performance with low sensitivity. With a good specificity, B72.3 may find use in an immunocytochemical panel for excluding benign mesothelial processes.


  • Impact of implementing the first edition of the Paris system for reporting: A systematic review and meta‐analysis

    by Sahar J. Farahani, Joshua Li, Beatrice Minder, Philippe Vielh, Marija Glisic, Taulant Muka

    Urine cytology is a noninvasive, widely used diagnostic tool for screening and surveillance of genitourinary tract neoplasms. However, the absence of unified terminology and clear objective morphological criteria limits the clinical benefit of urine cytology. The Paris System for Reporting Urine Cytology (TPS) was developed with the goal of standardizing reporting and improving urine cytology performance in detecting high‐grade malignancy (HGM). We aimed to evaluate potential effects of TPS on improving urine cytology diagnostic performance and clinical utility by conducting a systematic review and meta‐analysis. We searched six electronic databases to identify cross‐sectional and cohort studies written in English assessing the accuracy of urine cytology in detecting genitourinary tract malignancies of patients under surveillance or with clinical suspicion of malignancy from January 2004 to December 2022. We extracted relevant data from eligible studies to calculate relative distribution of cytology diagnostic categories; ratio of atypical to HGM cytology diagnosis; and risk of HGM (ROHGM) and HGM likelihood ratio (HGM‐LR) associated with cytology diagnostic categories. We used a generalized linear mixed model with logit transformation to combine proportions and multilevel mixed‐effect logistic regression to pool diagnostic accuracy measurements. We performed meta‐regression to evaluate any significant difference between TPS and non‐TPS cohorts. We included 64 studies for 99,796 combined total cytology samples, across 31 TPS and 49 non‐TPS cohorts. Pooled relative distribution [95% confidence interval (CI)] of negative for high‐grade urothelial carcinoma (NHGUC)/negative for malignancy (NM); atypical urothelial cells (AUC); suspicious for high‐grade urothelial carcinoma (SHGUC)/suspicious for malignancy (SM); low‐grade urothelial neoplasm (LGUN); and HGM categories among satisfactory cytology cases were 83.8% (80.3%–86.9%), 8.0% (6.0%–10.6%), 2.2% (1.4%–3.3%), 0.01% (0.0%–0.1%), and 4.2% (3.2%–5.5%) in TPS versus 80.8% (76.8–2.7%), 11.3% (8.6%–14.7%), 1.8% (1.2%–2.7%), 0.01% (0.0%–0.1%), and 3.3% (2.5%–4.3%) in non‐TPS cohorts. Adopting TPS classification resulted in a significant increase in the frequency of NHGUC and a reduction in AUC cytology diagnoses, respectively. The AUC/HGM ratio in TPS cohort was 2.0, which showed a statistically significant difference from the atypical/HGM ratio of 4.1 in non‐TPS cohort (p‐value: 0.01). Moreover, the summary rate (95% CI) of LGUN called AUC on cytology significantly decreased to 20.8% (14.9%–28.3%) in the TPS compared with 34.1% (26.4%–42.8%) in non‐TPS cohorts. The pooled ROHGM (95% CI) was 20.4% (6.2%–50.0%) in nondiagnostic (NDX), 15.5% (9.6%–24.2%) in NHGUC, 40.2% (30.9%–50.2%) in AUC, 80.8% (72.9%–86.8%) in SHGUC, 15.1% (5.7%–34.3%) in LGUN, and 91.4% (87.3%–94.3%) in HGM categories in TPS studies. NHGUC, AUC, SHGUC, and HGM categories were associated with HGM‐LR (95% CI) of 0.2 (0.1–0.3), 0.9 (0.6–1.3), 6.9 (2.4–19.9), and 16.8 (8.3–33.8). Our results suggest that TPS 1.0 has reduced the relative frequency of AUC diagnosis, AUC/HGM ratio, and the frequency of LGUNs diagnosed as AUC on cytology. Adopting this classification has improved the clinical utility of SHGUC and HGM cytology diagnoses in ruling in high‐grade lesions. However, an NHGUC diagnosis does not reliably rule out the presence of a high‐grade lesion.


  • Open Access

    An umbrella review of systematic reviews on the impact of the COVID-19 pandemic on cancer prevention and management, and patient needs

    by Taulant Muka, Joshua Jx Li, Sahar J Farahani, John Pa Ioannidis

    The relocation and reconstruction of health care resources and systems during the coronavirus disease 2019 (COVID-19) pandemic may have affected cancer care. An umbrella review was undertaken to summarize the findings from systematic reviews on impact of the COVID-19 pandemic on cancer treatment modification, delays, and cancellations; delays or cancellations in screening and diagnosis; psychosocial well-being, financial distress, and use of telemedicine as well as on other aspects of cancer care. Bibliographic databases were searched for relevant systematic reviews with or without meta-analysis published before November 29th, 2022. Abstract, full- text screening, and data extraction were performed by two independent reviewers. AMSTAR-2 was used for critical appraisal of included systematic reviews. Fifty-one systematic reviews were included in our analysis. Most reviews were based on observational studies judged to be at medium and high risk of bias. Only two reviews had high or moderate scores based on AMSTAR-2. Findings suggest treatment modifications in cancer care during the pandemic versus the pre-pandemic period were based on low level of evidence. Different degrees of delays and cancellations in cancer treatment, screening, and diagnosis were observed, with low- and- middle- income countries and countries that implemented lockdowns being disproportionally affected. A shift from in-person appointments to telemedicine use was observed, but utility of telemedicine, challenges in implementation and cost-effectiveness in cancer care were little explored. Evidence was consistent in suggesting psychosocial well-being of patients with cancer deteriorated, and cancer patients experienced financial distress, albeit results were in general not compared to pre-pandemic levels. Impact of cancer care disruption during the pandemic on cancer prognosis was little explored. In conclusion, substantial but heterogenous impact of COVID-19 pandemic on cancer care has been observed.


  • Retrospective assessment of the effectiveness of the Milan system for reporting salivary gland cytology: A systematic review and meta‐analysis of published literature

    by Sahar J Farahani, Zubair Baloch

    Introduction: Fine needle aspiration (FNA) has been widely utilized in establishing the nature of salivary gland lesions and guiding the clinical management. This study aimed to determine the accuracy of FNA in detecting salivary gland neoplasms and malignancies, employing the “Milan System for Reporting Salivary Gland Cytopathology” (MSRSGC).Method: A systematic search was conducted. The data on FNA and histologic diagnosis were extracted and categorized based on the MSRSGC and risk of malignancy (ROM) was calculated. The risk of publication bias and level of heterogeneity were evaluated. A mixed‐effects model was used to estimate FNA accuracy. Meta‐regression was conducted to assess the potential effect of different variables on FNA accuracy.Results: Ninety‐two studies with a total of 16 456 FNA with surgical follow‐up were included. ROM was estimated as 17%, 8%, 34%, 4%, 42%, 58%, and 91%, in nondiagnostic, nonneoplastic, atypia of undetermined significance, benign neoplasm, salivary gland neoplasm of uncertain malignant potential, suspicious for malignancy, and malignant groups, respectively. High level of heterogeneity was detected (P‐value <.001). Including cases with definite FNA diagnosis of neoplasm or malignancy, summary estimates of FNA sensitivity, specificity, diagnostic odds ratio, and positive and negative likelihood ratio in detecting neoplasms and malignancies were 96.9%, 95.3%, 636.8, 20.5, and 0.03, and 80.5%, 97.9%, 189.5, 37.8, and 0.2, respectively. Meta‐regression showed several variables significantly impacting FNA accuracy; however, subgroup analysis did not reduce the level of heterogeneity.Conclusion: FNA can be used as a reliable diagnostic tool in the preoperative evaluation and management of salivary glands lesions. Concise of abstract is using Milan system for reporting salivary gland FNA could increase FNA reliability, facilitate communication, and improve patient care.